The head of Google's life sciences team drummed up already-high interest in the company's developmental stage wearable diagnostic. The device will use magnets to "call" diagnostic nanoparticles so small that millions fit within a grain of sand, said life science team leader and Google X lab member Andrew Conrad at the WSJD Live conference
Google is going after your genome. The search giant has spent the past 18 months building its Google Genomics platform and pitching it to researchers as a way to store human genomes for $25 each per year.
The space occupied by Google Flu Trends is becoming more congested. One year after the Centers for Disease Control and Prevention put out a call for ways to use digital data to forecast the flu season, details of the entrants' models are still trickling in as academic papers are published.
Diagnostics luminary Foundation Medicine is generating some upward momentum, fueled by growing revenues and the success of its clinical tests. Tech giant Google has taken note and is signing onto the company's cancer diagnostics by offering them to employees.
Google has made the biggest change to its Flu Trends influenza tracking software since it first released the system in 2008. The update incorporates data from the Centers for Disease Control and Prevention in an attempt to improve the accuracy of the model.
Google has dedicated more than 100 employees from multiple disciplines to making its vision of nanotechnology-enabled detection of cancer and other diseases a reality. Any tangible product resulting from this ambitious effort is at least 5 to 7 years away.
The list of life science data projects underpinned by Google keeps getting longer. Having signed up to the BRAIN Initiative last week, Google has now teamed up with ISB and SRA International to work on a project for the National Cancer Institute.
The National Institutes of Health has kicked off the BRAIN Initiative by awarding $46 million to 58 projects. And Google has come on board as a commercial partner to develop software and infrastructure to handle the petabyte-scale data sets the projects are expected to generate.
While the outside world still has little idea what Google's biotech Calico is planning, AbbVie has seen enough to convince it to commit at least $250 million to the startup.
Hot on the heels of its $805 million development deal with Infinity, AbbVie Pharmaceuticals has followed up today with a plan to partner with Google's closely watched biotech upstart Calico on a new research operation that will cost up to $1.5 billion to get started.